Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England.
Adult
Blood Glucose
/ analysis
Blood Glucose Self-Monitoring
/ instrumentation
COVID-19
/ epidemiology
Clinical Audit
Communicable Disease Control
/ methods
Computer Systems
Diabetes Mellitus, Type 1
/ blood
England
/ epidemiology
Female
Health Services Accessibility
/ organization & administration
Hospitals, Teaching
Humans
Insulin
/ administration & dosage
Insulin Infusion Systems
Male
Middle Aged
Pandemics
Quarantine
Remote Sensing Technology
/ instrumentation
Retrospective Studies
SARS-CoV-2
/ physiology
Telemedicine
/ instrumentation
COVID-19 lockdown
Flash glucose monitoring
Real-time continuous glucose monitoring
Type 1 diabetes
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
08
2020
accepted:
01
10
2020
pubmed:
18
10
2020
medline:
25
2
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
People with type 1 diabetes (T1D) face the daily task of implementing self-management strategies to achieve their glycaemic goals. The UK COVID-19 lockdown has had an impact on day-to-day behaviour, which may affect diabetes self-management and outcomes. We assessed whether sensor-based outcomes pre- and during lockdown periods were different in a cohort of glucose sensor users with T1D. Data were collected from Freestyle Libre (FSL) or Dexcom G6 sensor users who remotely shared their data with the diabetes clinic web platform. Sensor metrics according to international consensus were analysed and compared between pre-lockdown period and 2 and 3 weeks into lockdown (periods 1 and 2). Two hundred and sixty-nine T1D patients (baseline HbA1c 57 ± 14 mmol/mol) were identified as FSL (n = 190) or Dexcom G6 (n = 79) users. In patients with sensor use > 70% (N = 223), compared to pre-lockdown period percentage TIR 3.9-10 mM (TIR) significantly increased during period 1 (59.6 ± 18.2 vs. 57.5 ± 17.2%, p = 0.002) and period 2 (59.3 ± 18.3 vs. 57.5 ± 17.2%, p = 0.035). The proportion of patients achieving TIR ≥ 70% increased from 23.3% pre-lockdown to 27.8% in period 1 and 30.5% in period 2. A higher proportion also achieved the recommended time below and above range, and coefficient of variation in periods 1 and 2. Dexcom G6 users had significantly lower % time below range (< 3.9 mM) compared to FSL users during both lockdown periods (period 1: Dexcom G6 vs. FSL: 1.8% vs. 4%; period 2: 1.4% vs. 4%, p < 0.005 for both periods). Sensor-based glycaemic outcomes in people with T1D in the current cohort improved during COVID-19 lockdown, which may be associated with positive changes in self-management strategies. Further work is required to evaluate long-term sustainability and support.
Identifiants
pubmed: 33067723
doi: 10.1007/s00592-020-01614-5
pii: 10.1007/s00592-020-01614-5
pmc: PMC7567414
doi:
Substances chimiques
Blood Glucose
0
Insulin
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
231-237Références
DiMeglio LA, Evans-Molina C, Oram RA (2018) Type 1 diabetes, Lancet 391(10138):2449–2462. https://doi.org/10.1016/S0140-6736(18)31320-5
doi: 10.1016/S0140-6736(18)31320-5
pubmed: 29916386
pmcid: 29916386
Chatterjee S, Davies MJ (2015) Current management of diabetes mellitus and future directions in care, Postgrad Med J 91(1081):612–621. https://doi.org/10.1136/postgradmedj-2014-133200
doi: 10.1136/postgradmedj-2014-133200
pubmed: 26453594
McCarthy MM, Grey M (2018) Type 1 diabetes self-management from emerging adulthood through older adulthood, Diabetes Care 41(8):1608–1614. https://doi.org/10.2337/dc17-2597
doi: 10.2337/dc17-2597
pubmed: 29802144
van Duinkerken E, Snoek FJ, de Wit M (2019) The cognitive and psychological effects of living with type 1 diabetes: a narrative review, Diabet Med. https://doi.org/10.1111/dme.14216
doi: 10.1111/dme.14216
pubmed: 31850538
pmcid: 7154747
Riazi A, Pickup J, Bradley C (2004) Daily stress and glycaemic control in type 1 diabetes: individual differences in magnitude, direction, and timing of stress-reactivity, Diabetes Res ClinPract 66(3):237–244. https://doi.org/10.1016/j.diabres.2004.04.001
doi: 10.1016/j.diabres.2004.04.001
Trento M et al (2009) Quality of life, coping ability, and metabolic control in patients with type 1 diabetes managed by group care and a carbohydrate counting program, Diabetes Care 32(11):e134. https://doi.org/10.2337/dc09-0903
doi: 10.2337/dc09-0903
pubmed: 19875597
Prime Minister's statement on coronavirus (COVID-19) 2020, https://www.gov.uk/government/speeches/pm-address-to-the-nation-on-coronavirus-23-march-2020
Coronavirus Act 2020, https://www.legislation.gov.uk/ukpga/2020/7/contents/enacted , ed
Evans M, Welsh Z, Ells S, Seibold A (2020) The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies, Diabetes Ther 11(1):83–95. https://doi.org/10.1007/s13300-019-00720-0
doi: 10.1007/s13300-019-00720-0
pubmed: 31673972
Foster NC et al (2019) State of type 1 diabetes management and outcomes from the T1D exchange in 2016–2018, Diabetes TechnolTher 21(2):66–72. https://doi.org/10.1089/dia.2018.0384
doi: 10.1089/dia.2018.0384
Aleppo G et al (2017) REPLACE-BG: a randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes, Diabetes Care 40(4):538–545. https://doi.org/10.2337/dc16-2482
doi: 10.2337/dc16-2482
pubmed: 28209654
pmcid: 5864100
Rodbard D (2017) Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes, Diabetes TechnolTher 19(S3):S25–S37. https://doi.org/10.1089/dia.2017.0035
doi: 10.1089/dia.2017.0035
Battelino T et al (2019) Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range, Diabetes Care 42(8):1593–1603. https://doi.org/10.2337/dci19-0028
doi: 10.2337/dci19-0028
pubmed: 31177185
pmcid: 6973648
Nathan DM et al (2008) Translating the A1C assay into estimated average glucose values, Diabetes Care 31(8):1473–1478. https://doi.org/10.2337/dc08-0545
doi: 10.2337/dc08-0545
pubmed: 18540046
pmcid: 2742903
Andrikopoulos S, Johnson G (2020) The Australian response to the COVID-19 pandemic and diabetes-Lessons learned, Diabetes Res ClinPract 165:108246. https://doi.org/10.1016/j.diabres.2020.108246
doi: 10.1016/j.diabres.2020.108246
Verma A, Rajput R, Verma S, Balania VKB, Jangra B (2020) Impact of lockdown in COVID 19 on glycemic control in patients with type 1 diabetes mellitus, Diabetes Metab Syndr 14(5):1213–1216. https://doi.org/10.1016/j.dsx.2020.07.016
doi: 10.1016/j.dsx.2020.07.016
pubmed: 32679527
pmcid: 7357511
Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP (2020) Glycaemic control among people with type 1 diabetes during lockdown for the SARS-CoV-2 outbreak in Italy, Diabetes Ther. 11:1369–1379. https://doi.org/10.1007/s13300-020-00829-7
doi: 10.1007/s13300-020-00829-7
Mesa A et al (2020) The impact of strict COVID-19 lockdown in Spain on glycemic profiles in patients with type 1 diabetes prone to hypoglycemia using standalone continuous glucose monitoring, Diabetes Res ClinPract 167:108354. https://doi.org/10.1016/j.diabres.2020.108354
doi: 10.1016/j.diabres.2020.108354
Dover AR et al (2020) Assessment of the effect of the COVID-19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring, Diabet Med. https://doi.org/10.1111/dme.14374
doi: 10.1111/dme.14374
pubmed: 33128811
pmcid: 7436620
Deshmukh H et al (2020) Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit, Diabetes Care. https://doi.org/10.2337/dc20-0738
doi: 10.2337/dc20-0738
pubmed: 32669277
pmcid: 7440900
Ghosh A, Arora B, Gupta R, Anoop S, Misra A (2020) Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in North India, Diabetes Metab Syndr 14(5):917–920. https://doi.org/10.1016/j.dsx.2020.05.044
doi: 10.1016/j.dsx.2020.05.044
pubmed: 32574982
pmcid: 7265851
Ghosal S, Arora B, Dutta K, Ghosh A, Sinha B, Misra A (2020) Increase in the risk of type 2 diabetes during lockdown for the COVID19 pandemic in India: a cohort analysis, Diabetes Metab Syndr 14(5):949–952. https://doi.org/10.1016/j.dsx.2020.06.020
doi: 10.1016/j.dsx.2020.06.020
pubmed: 32604013
pmcid: 7303633
https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/report-1-care-processes-and-treatment-targets-2017-18-full-report , ed
National Institute for Health and Care Excellence, type 1 diabetes in adults: diagnosis and management, https://www.nice.org.uk/guidance/ng17